Henlius Wins NMPA Nod to Trial Novel CD47-Targeting Fusion Protein in Advanced Colorectal Cancer

An update from Shanghai Henlius Biotech, Inc. Class H ( (HK:2696) ) is now available.

Shanghai Henlius Biotech has received approval from China’s National Medical Products Administration for an investigational new drug application to conduct a phase 1b/2 clinical trial of HLX701, a recombinant human SIRPα–IgG4 Fc fusion protein injection, in combination with cetuximab and chemotherapy for the treatment of advanced colorectal cancer. HLX701, in-licensed from FBD Biologics, targets CD47 on tumour cells to enhance macrophage-mediated phagocytosis and anti-tumour activity, and preclinical data suggest synergistic effects when combined with chemotherapy, immune checkpoint inhibitors, EGFR inhibitors and other targeted drugs; with no SIRPα-Fc fusion protein targeting CD47 yet approved globally, this programme could strengthen Henlius’s pipeline in solid tumours and potentially improve its competitive positioning in the oncology biologics market if clinical development progresses successfully.

The most recent analyst rating on (HK:2696) stock is a Hold with a HK$74.00 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.

More about Shanghai Henlius Biotech, Inc. Class H

Shanghai Henlius Biotech, Inc. is a China-based biopharmaceutical company focused on developing, manufacturing and commercialising innovative biologic drugs and biosimilars, particularly for oncology and other serious diseases. The company operates primarily in mainland China with additional territorial rights in select Southeast Asian, Middle Eastern and North African markets, positioning itself as a regional player in advanced biologic therapies.

Average Trading Volume: 963,969

Technical Sentiment Signal: Buy

Current Market Cap: HK$37.09B

For detailed information about 2696 stock, go to TipRanks’ Stock Analysis page.